PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Paraldehyde in olive oil - Status epilepticus

PAD Profile : Paraldehyde in olive oil - Status epilepticus

Keywords :
paraldehyde enemas, paraldehyde 50% enema

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Rectal solution
Important Information :
Unlicensed product. Paediatrics only. GPs may continue prescribing for EXISTING patients where they are satisfied that it is safe to do so. Prescribing for new patients should remain with the initiating, specialist team.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
U
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
04 December 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a RED traffic light status for the use of paraldehyde Olive Oil Enemas to treat seizures or status epilepticus.

Patients currently being prescribed paraldehyde olive oil enemas in primary care may continue if, following discussions with the patient / carer, the prescriber is satisfied that the treatment is appropriate and there are no safety concerns.

For all new patients prescribing should remain with the specialist team that initiated the treatment.

Associated BNF Codes

04. Central Nervous System
04.08.02. Drugs used in status epilepticus
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More